Clovis Oncology Yönetim
Yönetim kriter kontrolleri 3/4
Clovis Oncology CEO'su Patrick Mahaffy, Apr2009 tarihinde atandı, in görev süresi 14.25 yıldır. şirketin hisselerinin 0.67% doğrudan sahiptir ve bu hisselerin değeri $ 14.56K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.4 yıl ve 14.3 yıldır.
Anahtar bilgiler
Patrick Mahaffy
İcra Kurulu Başkanı
n/a
Toplam tazminat
CEO maaş yüzdesi | n/a |
CEO görev süresi | 14.3yrs |
CEO sahipliği | 0.7% |
Yönetim ortalama görev süresi | 7.4yrs |
Yönetim Kurulu ortalama görev süresi | 14.3yrs |
Son yönetim güncellemeleri
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2022 | n/a | n/a | -US$252m |
Jun 30 2022 | n/a | n/a | -US$263m |
Mar 31 2022 | n/a | n/a | -US$258m |
Dec 31 2021 | US$3m | US$739k | -US$265m |
Sep 30 2021 | n/a | n/a | -US$299m |
Jun 30 2021 | n/a | n/a | -US$310m |
Mar 31 2021 | n/a | n/a | -US$336m |
Dec 31 2020 | US$3m | US$721k | -US$369m |
Sep 30 2020 | n/a | n/a | -US$370m |
Jun 30 2020 | n/a | n/a | -US$385m |
Mar 31 2020 | n/a | n/a | -US$413m |
Dec 31 2019 | US$7m | US$719k | -US$400m |
Sep 30 2019 | n/a | n/a | -US$400m |
Jun 30 2019 | n/a | n/a | -US$396m |
Mar 31 2019 | n/a | n/a | -US$377m |
Dec 31 2018 | US$6m | US$689k | -US$368m |
Sep 30 2018 | n/a | n/a | -US$321m |
Jun 30 2018 | n/a | n/a | -US$291m |
Mar 31 2018 | n/a | n/a | -US$366m |
Dec 31 2017 | US$9m | US$636k | -US$346m |
Sep 30 2017 | n/a | n/a | -US$365m |
Jun 30 2017 | n/a | n/a | -US$370m |
Mar 31 2017 | n/a | n/a | -US$324m |
Dec 31 2016 | US$789k | US$224k | -US$349m |
Tazminat ve Piyasa: Patrick şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.
Tazminat ve Kazançlar: Patrick 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Patrick Mahaffy (60 yo)
14.3yrs
Görev süresi
US$2,639,083
Tazminat
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Executive VP & CFO | 7.3yrs | US$1.19m | 0.072% $ 1.6k | |
Executive VP | 7.5yrs | US$1.20m | 0.068% $ 1.5k | |
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer | 7.9yrs | US$1.24m | 0.078% $ 1.7k | |
Executive VP & Chief Scientific Officer | 3.8yrs | Veri yok | Veri yok | |
Executive Vice President of Human Resources | 6.8yrs | Veri yok | Veri yok |
7.4yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: CLVS.Q 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.4 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Independent Director | 14.3yrs | US$260.00k | 0.041% $ 889.9 | |
Independent Director | 14.5yrs | US$270.00k | 0.040% $ 875.1 | |
Independent Director | 14.5yrs | US$270.00k | 0.17% $ 3.8k | |
Independent Director | 14.5yrs | US$270.00k | 0.044% $ 953.2 | |
Independent Chairman | 10.5yrs | US$287.50k | 0% $ 0 | |
Independent Director | 14.5yrs | US$257.50k | 0.040% $ 872.7 | |
Director | 2yrs | US$375.21k | Veri yok | |
Independent Director | 10.5yrs | US$259.58k | 0% $ 0 | |
Independent Director | 4.8yrs | US$257.50k | 0% $ 0 | |
Independent Director | 4.8yrs | US$255.00k | 0% $ 0 |
14.3yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CLVS.Q 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14.3 yıldır).